Randomized clinical trials with biomarkers: design issues. - Wikidata - awgldk - TriplyDB

Randomized clinical trials with biomarkers: design issues.

Randomized clinical trials with biomarkers: design issues.

http://www.wikidata.org/entity/Q34024227

about

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside Molecular and clinical implementations of ovarian cancer mouse avatar models Personalized Medicine: Genomics Trials in Oncology Biomarker validation and testing Cancer biomarkers Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review Optimizing Trial Designs for Targeted Therapies The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.Strategies for power calculations in predictive biomarker studies in survival data Adjusting for misclassification in a stratified biomarker clinical trial.Randomized reverse marker strategy design for prospective biomarker validation Designing biomarker studies for head and neck cancer.Overview of a chemoresponse assay in ovarian cancer Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study Statins and breast cancer prognosis: evidence and opportunities.Criteria for the use of omics-based predictors in clinical trials.Statistical challenges in the development and evaluation of marker-based clinical tests.Charting a roadmap for heart failure biomarker studies.Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).Benchmarks for detecting 'breakthroughs' in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation.Contribution of biomarkers to personalized medicine.Methods and challenges in quantitative imaging biomarker development Outcome--adaptive randomization: is it useful?Fool's gold, lost treasures, and the randomized clinical trial.Clinical trial designs for testing biomarker-based personalized therapies.The direct assignment option as a modular design component: an example for the setting of two predefined subgroups Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.Evaluation of chemoresponse assays as predictive markers Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 How close are we to customizing chemotherapy in early non-small cell lung cancer?Adaptive clinical trial designs in oncology.Evaluating many treatments and biomarkers in oncology: a new design Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility.Clinical trials in the era of personalized oncology.

P2860

Q26770678-174A1AFB-B339-4056-B5CD-CB9689DE69F2 Q26786724-5F6D8728-2145-4CD9-9C19-F582C011C51F Q26795376-51D80B19-EA32-4718-BED1-657EF1011795 Q26863672-F408BF6E-1685-4EC2-BF3E-2BFB7AA5CEC1 Q26864429-76EFF823-E8C3-4635-8ADD-DC6813412378 Q26865266-6CCEDD77-F2EB-4969-A1A2-3D5E1FE1BC78 Q26992272-2088C21D-C95D-4022-AB88-5914A3B44685 Q28066738-4DAC4FCE-F7E7-4E39-9EEA-209ECA6A16B7 Q28079118-E3B13CD6-8ADC-4D8E-A08D-AA96B06F0F1B Q28086970-B5600971-67BF-4235-9464-A8A730A0D20A Q28554393-231D69DB-4757-439A-9222-D70F4DE16EF7 Q30235485-6C5A2B41-AF1F-402C-A883-C3939542E02B Q30514241-E76CDFB9-393D-4F84-AA9F-B1DCDDDC91C9 Q31132692-240A19A0-E412-4480-82FA-E276D18BDFAC Q33934232-09CBA455-8FC5-4EFB-BD46-2C1F82EFF005 Q33934952-D22C870B-58A2-4397-A479-17D76CD3F05A Q33971467-26F80904-E771-4680-9E78-116274D0F040 Q34071625-DA94DD54-5DD9-4290-ACCB-A4E0B16672F3 Q34113564-651B7573-349F-4F07-96B0-EE1A91EFA8BD Q34206487-DBE02750-476D-4C31-84B6-EC2F314B0746 Q34269875-353E53C0-8FE4-4637-AC51-8DCFDE94EA14 Q34285269-8273F78D-87E4-4990-A3D1-1DF07F68EEB5 Q34324812-C6D13302-6C1E-4871-A876-A89D69E94893 Q34366871-CA3F451E-05FA-4CED-BE2E-FC5C71CAB155 Q34367452-9E70F848-FE01-4D92-82B2-737D18FDB5CE Q34397235-E5A3E921-C7ED-4561-A021-980C698A134C Q34423459-1FB6F0BA-E76B-492F-B408-C8D8B2EE0EB9 Q34648114-02081EF3-3675-475B-A105-AA9618E46064 Q34667846-48753613-2E66-4DEF-9DFB-4FF9A6903C02 Q34669260-70219B8F-2186-4830-94E7-018D3C4185FE Q34977663-94B0B4CF-F08D-42D0-82DF-6DCC63271056 Q35026541-1B03837F-5824-4549-BC56-BCDF23010F3A Q35042433-CEB60B64-6881-49E5-95DC-C1D09C60CE80 Q35098338-0861A54B-3DE3-4C96-AB02-17F1136DF9FA Q35136424-299904D7-132A-4C78-9E64-71A9C5E21A33 Q35146944-30A6801C-3C09-4325-B0D2-35D633314016 Q35206844-439D352E-E038-4BDD-A05F-88C8F27CDAD5 Q35379179-277845A0-172F-4D16-84D5-F1F6A7C2E711 Q35538902-0614E671-5348-49A9-9ABB-D913F87D26D7 Q35555963-7FF6CC81-191B-4808-91FD-9EC36931E37F

P2860

Randomized clinical trials with biomarkers: design issues.

http://www.wikidata.org/entity/Q34024227

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Randomized clinical trials with biomarkers: design issues.

@ast

Randomized clinical trials with biomarkers: design issues.

@en

Randomized clinical trials with biomarkers: design issues.

@nl

type

label

Randomized clinical trials with biomarkers: design issues.

@ast

Randomized clinical trials with biomarkers: design issues.

@en

Randomized clinical trials with biomarkers: design issues.

@nl

prefLabel

Randomized clinical trials with biomarkers: design issues.

@ast

Randomized clinical trials with biomarkers: design issues.

@en

Randomized clinical trials with biomarkers: design issues.

@nl

P1433

Q34024227-EA20A7D7-AC64-4FA0-BAEA-D9B704DC011E

P1476

Q34024227-059DF3E1-58FC-4B6F-9864-6085872FD972

P2093

Q34024227-0A1243B7-28FA-4307-8687-65789E5A9E21

Q34024227-E419DEF0-3A38-4FC8-A7BA-CE178C793902

P2860

Q34024227-0079804C-4854-4DFD-B3CF-6D4E8632F3E9

Q34024227-042A8A47-B7CF-49AE-858F-2AAF89C784B2

Q34024227-1D675E68-EFC2-44C7-93ED-056DD33F7F40

Q34024227-2D09437E-ED5D-4F2A-976D-B389ACD740B3

Q34024227-2D4F688F-3084-422C-81BD-32C8CF40866C

Q34024227-3556D043-2BEB-4F6A-B9F5-DF8D484F7526

Q34024227-593A67E2-5C61-4F05-AA3B-F3C908901A87

Q34024227-5CE95509-516A-4C2E-BF87-F2020FC6AB60

Q34024227-6B660550-3C92-4967-AB7A-6F9CF3B5EE0A

Q34024227-8E5A7850-F1B3-44EA-8AC7-259084D66DF8

P304

Q34024227-15A0C987-5285-47E1-B776-184F1FC71239

P31

Q34024227-9490A250-3330-47EC-900C-CDE04F75DF98

P356

Q34024227-2494AC15-A6DB-451A-AD1E-B1EA9E236927

P407

Q34024227-9859190D-A33C-4468-BE71-91E6E6B03820

P433

Q34024227-3B42513E-996A-4240-BFE9-C290CEA48BEF

P478

Q34024227-531A973F-D600-46B5-93B3-5CBF7ACBD964

P50

Q34024227-E9FDEA66-BC1D-432F-8823-19A04707C4F1

P577

Q34024227-5651C575-108F-4F41-9B58-8E145121C172

P5875

Q34024227-8F231117-E769-4E41-AF84-80AC33C7A52A

P698

Q34024227-FC640006-E813-4BD7-A5C2-136BCAC56842

P921

Q34024227-C1738FAB-E650-4A0A-A2B2-778C1472E750

P932

Q34024227-4222055F-4C5D-4FE3-9C7D-6EF658ED1FA9

P356

P1433

Journal of the National Cancer Institute

P1476

Randomized clinical trials with biomarkers: design issues.

@en

P2093

Edward L Korn

http://www.w3.org/2001/XMLSchema#string

Lisa M McShane

http://www.w3.org/2001/XMLSchema#string

P2860

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

A multiple testing procedure for clinical trials

Clinical trial designs for predictive marker validation in cancer treatment trials

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

The roles of FLT3 in hematopoiesis and leukemia.

Clinical trial design for microarray predictive marker discovery and assessment.

Clinical trials design and treatment tailoring: general principles applied to breast cancer research.

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.

Monitoring for lack of benefit: a critical component of a randomized clinical trial

The use of genomics in clinical trial design.

P304

152-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJP477

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41028391

http://www.w3.org/2001/XMLSchema#string

P698

20075367

http://www.w3.org/2001/XMLSchema#string

P921

P932

2911042

http://www.w3.org/2001/XMLSchema#string